VDAC1 and neoplasm: In this study, using a carcinogen-induced lung cancer that is very close to human developed lung cancer, we demonstrated that siRNA against VDAC1 encapsulated in PLGA-PEI nanoparticles and VDAC1-based peptides developed in our lab [25,26] when given intravenously reached the lung tumors, effectively attenuating tumor growth and reversing their oncogenic properties.